home / stock / aphb / aphb quote
Last: | $ |
---|---|
Change Percent: | -20.33% |
Open: | $0.347 |
Close: | $0.3179 |
High: | $0.359 |
Low: | $0.3086 |
Volume: | 4,538,981 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$ | $0.347 | $0.3179 | $0.359 | $0.3086 | 4,538,981 | 05-09-2019 |
$ | $0.39 | $0.399 | $0.445 | $0.37 | 9,508,871 | 05-08-2019 |
$ | $0.359 | $0.37 | $0.385 | $0.35 | 1,733,965 | 05-07-2019 |
$ | $0.332 | $0.376 | $0.39 | $0.3201 | 2,600,047 | 05-06-2019 |
$ | $0.40 | $0.332 | $0.4149 | $0.319 | 6,407,977 | 05-03-2019 |
$ | $0.3107 | $0.38 | $0.39 | $0.30 | 6,018,598 | 05-02-2019 |
$ | $0.314 | $0.3104 | $0.34 | $0.31 | 772,796 | 05-01-2019 |
$ | $0.289 | $0.34 | $0.3461 | $0.283 | 2,746,258 | 04-30-2019 |
$ | $0.2956 | $0.29 | $0.30 | $0.283 | 277,581 | 04-29-2019 |
$ | $0.309 | $0.2956 | $0.309 | $0.293 | 76,732 | 04-26-2019 |
$ | $0.2948 | $0.2943 | $0.3012 | $0.2905 | 186,899 | 04-25-2019 |
$ | $0.342 | $0.3012 | $0.342 | $0.2905 | 196,801 | 04-24-2019 |
$ | $0.335 | $0.3089 | $0.335 | $0.3005 | 111,349 | 04-23-2019 |
$ | $0.32 | $0.3067 | $0.325 | $0.281 | 656,979 | 04-22-2019 |
$ | $0.335 | $0.3176 | $0.34 | $0.305 | 303,551 | 04-19-2019 |
$ | $0.335 | $0.3176 | $0.34 | $0.305 | 295,342 | 04-18-2019 |
$ | $0.35 | $0.3249 | $0.36 | $0.30 | 1,362,432 | 04-17-2019 |
$ | $0.35 | $0.352 | $0.38 | $0.3356 | 1,256,494 | 04-16-2019 |
$ | $0.34 | $0.34 | $0.36 | $0.33 | 920,175 | 04-15-2019 |
$ | $0.2939 | $0.346 | $0.3666 | $0.29 | 3,904,041 | 04-12-2019 |
News, Short Squeeze, Breakout and More Instantly...
AmpliPhi Biosciences Corporation Company Name:
APHB Stock Symbol:
NYSE Market:
AmpliPhi Biosciences Corporation (NYSE American: APHB) , a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced that its stockholders voted to approve the proposals required to complete the busines...
Entered into a merger agreement with C3J Therapeutics that is expected to result in an NYSE American-listed company (to be named Armata Pharmaceuticals) focused on development of precisely targeted bacteriophage therapeutics $10.0 million of new capital to be invested in combined co...
Entered into a merger agreement with C3J Therapeutics that is expected to result in an NYSE American-listed company focused on development of precisely-targeted bacteriophage therapeutics $10.0 million of new capital will be invested in combined company to be re-named Armata Pharmac...